National Institute on Child Health and Human Development (NICHD) - For More Information Date: March 17, 1997 National Institute on Child Health and Human Development P.O. Box 29111 Washington, D.C. 20040 (301) 496-5133 Fax: (301) 496-7101 http://www. nichd.nih.gov For information on the more than 100 scientific and medical societies and health advocacy groups connected with NICHD research, contact Friends of the NICHD, a coalition that lobbies for the institute's goals: Friends
National Institute on Child Health and Human Development
P.O. Box 29111
Washington, D.C. 20040
(301) 496-5133
Fax: (301) 496-7101
http://www. nichd.nih.gov
For information on the more than 100 scientific and medical societies and health advocacy groups connected with NICHD research, contact Friends of the NICHD, a coalition that lobbies for the institute's goals:
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
